Skip to main content
SpringerLink
Log in

Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults

  • Review Article
  • Cost Effectiveness of Chd Prevention Strategies
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Although risk-factor modification has gained wide acceptance as an effective approach to the prevention of coronary heart disease (CHD), health planners, physicians and patients confront considerable uncertainty over the most appropriate and efficient preventive strategies. Some preventive approaches are both inexpensive and effective; others are expensive while their effectiveness is slight or unproven. Effectiveness varies with an individual’s age, gender and other risk factors. Information provided by a cost—effectiveness analysis can clarify the value of alternative strategies for CHD prevention in specific populations, thereby helping to choose among them. It does so by producing a standard measure of value — the cost per year of life saved (YLS) or cost per quality—adjusted life—year (QALY) saved — that reveals which of several alternative interventions provides the greatest health benefit from a given expenditure. This article summarises the extensive literature on the cost effectiveness of CHD prevention with an emphasis on primary prevention.

Published work indicates that smoking—cessation programmes, particularly those that rely on counselling with or without nicotine supplements, are highly cost effective in many settings. Although the evidence is limited, exercise programmes also appear to be cost effective. The detection and treatment of hypertension is highly cost effective, particularly when inexpensive drugs with proven effectiveness, such as diuretics or β—blockers, are used. Hormone—replacement therapy is a cost—effective approach to CHD prevention in most postmenopausal women, although direct clinical trial data are lacking and it is uncertain which hormone preparation is best. Cholesterol reduction is a cost—effective strategy for the prevention of CHD in individuals without other treatable risk factors who are at very high risk of developing CHD. For individuals with multiple CHD risk factors, the choice of risk—modification strategies is complex and depends upon the interactions of risk and the relative costs of treating each risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Robinson JG, Leon AS. The prevention of cardiovascular disease: emphasis on secondary prevention. Med Clin North Am 1994; 78: 69–98

    PubMed  CAS  Google Scholar 

  2. Oster G, Epstein AM. Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol. Am J Public Health 1986; 76: 647–56

    Article  PubMed  CAS  Google Scholar 

  3. Patrick DL, Erickson P. Health status and health policy: allocating resources to health care. New York: Oxford University Press, 1993: 1–478

    Google Scholar 

  4. The Multiple Risk Factor Intervention Trial (MRFIT): a national study of primary prevention of coronary heart disease. JAMA 1976; 235: 825–7

    Article  Google Scholar 

  5. Shea S, Cook EF, Kannel WB, et al. Treatment of hypertension and its effects on cardiovascular risk factors: data from the Framingham Heart Study. Circulation 1985; 71: 22–30

    Article  PubMed  CAS  Google Scholar 

  6. Kannel WB. Clinical misconceptions dispelled by epidemiological research. Circulation 1985; 92: 3350–60

    Article  Google Scholar 

  7. Keys A, Aravanis C, Blackburn HW, et al. Epidemiological studies related to coronary heart disease: characteristics of men aged 40—59 in seven countries. Acta Medica Sc and Suppl 1966; 460: 1–392

    CAS  Google Scholar 

  8. Weinstein MC, Stason WB. Hypertension: a policy perspective. Cambridge (MA): Harvard University Press, 1976

    Google Scholar 

  9. Gold MR, Siegel JE, Russell LB, et al., editors. Cost—effectiveness in health and medicine. New York: Oxford University Press, 1996

    Google Scholar 

  10. Patrick DL, Deyo RA. Generic and disease—specific measures in assessing health status and quality of life. Med Care 1989; 27: S217–32

    Article  PubMed  CAS  Google Scholar 

  11. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732–9

    Article  PubMed  CAS  Google Scholar 

  12. Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russel LB, et al., editors. Cost—effectiveness in health and medicine. New York: Oxford University Press, 1996: 82–134

    Google Scholar 

  13. McPherson K. International differences in medical care practices. In: Poullier JP, Schieber GJ, editors. Health care systems in transition: the search for efficiency. Paris: OECD, 1991: 17–28

    Google Scholar 

  14. Welch WP, Miller ME, Welch G, et al. Geographic variation in expenditures for physicians’ services in the United States. N Engl J Med 1993; 328: 621–7

    Article  PubMed  CAS  Google Scholar 

  15. Garber AM, Fuchs VR, Silverman JF. Case mix, costs, and outcomes: differences between faculty and community services in a university hospital. N Engl J Med 1984; 310: 1231–7

    Article  PubMed  CAS  Google Scholar 

  16. Kupersmith J, Holmes-Rovner M, Hogan A, et al. Cost—effectiveness analysis in heart disease. Part 1: general principles. Prog Cardiovasc Dis 1994; 37: 161–84

    Article  PubMed  CAS  Google Scholar 

  17. National Committee on Quality Assurance. Health plan employer data information set, 3.0. Washington, DC: National Committee on Quality Assurance, 1996

    Google Scholar 

  18. Oster G, Huse PM, Delea TE, et al. Cost—effectiveness of nicotine gum as an adjunct to physician’s advice against cigarette smoking. JAMA 1988; 256: 1315–8

    Article  Google Scholar 

  19. Neil HAW, Roe L, Godlee RJP, et al. Randomized trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ 1995; 310: 569–73

    Article  PubMed  CAS  Google Scholar 

  20. Altman DG, Flora JA, Fortman SD, et al. The cost—effectiveness of three smoking cessation programs. Am J Public Health 1987; 77: 162–5

    Article  PubMed  CAS  Google Scholar 

  21. Cummings SR, Rubin SM, Oster G. The cost—effectiveness of counselling smokers to quit. JAMA 1989; 261: 75–9

    Article  PubMed  CAS  Google Scholar 

  22. Krumholz HM, Cohen BJ, Tsevat J, et al. Cost—effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993; 22: 1697–702

    Article  PubMed  CAS  Google Scholar 

  23. Phillps CJ, Prowle MJ. Economics of a reduction in smoking: case study from Heartbeat Wales. J Epidemiol Community Health 1993; 47: 215–23

    Article  Google Scholar 

  24. Green LW, Johnson KW. Health education and health promotion. In: Mechanic D, editor. Handbook of health, health care, and the health professions. New York: The Free Press, 1997: 744–60

    Google Scholar 

  25. Tsevat J. Impact and cost—effectiveness of smoking interventions. Am J Med 1992; 93: 435–75

    Article  Google Scholar 

  26. Windsor RA, Warner KE, Cutter GR. A cost—effectiveness analysis of self—help smoking cessation methods for pregnant women. Public Health Rep 1988; 103: 83–7

    PubMed  CAS  Google Scholar 

  27. Poullier JP, Schieber GJ, editors. Organization for Economic Cooperation and Development (OECD). Health care systems in transition: the search for efficiency. Paris: OECD, 1990

    Google Scholar 

  28. Schectman G, Wolff N, Byrd JC, et al. Physician extenders for cost—effective management of hypercholesterolemia. J Gen Intern Med 1996; 11: 277–86

    Article  PubMed  CAS  Google Scholar 

  29. Hatziandreu EI, Koplan JP, Weinstein MC, et al. A cost effectiveness analysis of exercise as a health promotion activity. Am J Public Health 1988; 78: 1417–21

    Article  PubMed  CAS  Google Scholar 

  30. Jacoby DB. Letter. N Engl J Med 1986; 315: 399

    Article  Google Scholar 

  31. Consensus development conference on diet and exercise in noninsulindependent diabetes mellitus. Diabetes Care 1987; 10: 639–44

  32. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37

    PubMed  CAS  Google Scholar 

  33. Daly E, Roche M, Barlow D, et al. HRT: an analysis of benefits, risks and costs. Br Med Bull 1992; 48: 368–400

    PubMed  CAS  Google Scholar 

  34. Tosteson ANA. Hormone replacement therapy: benefit, risk and cost considerations. J Clin Pharmacol 1994; 34: 719–22

    PubMed  CAS  Google Scholar 

  35. Goddard M. The cost effectiveness of hormone replacement therapy: a review. York: Centre for Health Economics, University of York, 1990. Discussion paper no.: 73

    Google Scholar 

  36. Tosteson ANA, Rosenthal DI, Melton LJ, et al. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densiometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594–603

    PubMed  CAS  Google Scholar 

  37. Lobo RA. Benefits and risk of estrogen replacement therapy. Am J Obstet Gynecol 1995; 173: 982–9

    Article  PubMed  CAS  Google Scholar 

  38. Delva MD. Hormone replacement therapy: risks, benefits, and costs. Can Fam Physician 1993; 39: 2149–54

    PubMed  CAS  Google Scholar 

  39. Falkeborn M, Persson F, Apomamai HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen—progestogen replacement. Br J Obstet Gynecol 1992; 99: 821–8

    Article  CAS  Google Scholar 

  40. Weinstein MC, Schiff I. Cost—effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 1983; 38: 445–55

    Article  PubMed  CAS  Google Scholar 

  41. Weinstein MC, Tosteson AN. Cost—effectiveness of hormone replacement. Ann NY Acad Sci 1990; 592: 162–72

    Article  PubMed  CAS  Google Scholar 

  42. Cheung AP, Wren BG. A cost—effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 1992; 156: 312–6

    PubMed  CAS  Google Scholar 

  43. Pilote L, Hlatky MA. Attitudes of women toward hormone therapy and prevention of heart disease. Am Heart J 1995; 129: 1237–8

    Article  PubMed  CAS  Google Scholar 

  44. Kawachi I, Malcolm LA. The cost—effectiveness of treating mild—to—moderate hypertension: a reappraisal. J Hypertens 1991; 9: 199–208

    Article  PubMed  CAS  Google Scholar 

  45. Lawrence WF, Fryback DG, Martin PA, et al. Health status and hypertension: a population based study. J Clin Epidemiol 1996; 49: 1239–45

    Article  PubMed  CAS  Google Scholar 

  46. Stevens RD, Bingley LJ, Boger M, et al. Variability in the management of hypertension and cost—effectiveness: methodology, community care results and potential cost. Soc Sci Med 1984; 296: 732–9

    Google Scholar 

  47. Littenberg B, Garber AM, Sox HC. Screening for hypertension. Ann Intern Med 1990; 112: 192–202

    PubMed  CAS  Google Scholar 

  48. Edelson JT, Weinstein MC, Tosteson ANA, et al. Long—term cost—effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263: 407–13

    Article  PubMed  CAS  Google Scholar 

  49. Johannesson M, Dahlof B, Lindholm LH, et al. The cost—effectiveness of treating hypertension in elderly people: an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Inter Med 1993; 234: 317–23

    Article  CAS  Google Scholar 

  50. Ramsay LE, Yeo WW, Jackson PR. Thiazide diuretics; first—line therapy for hypertension. J Hypertens 1992; 10: 529–33

    Article  Google Scholar 

  51. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM study. Ann Intern Med 1991; 114: 613–20

    PubMed  CAS  Google Scholar 

  52. Cantor JC, Morisky DE, Green LW, et al. Cost—effectiveness of educational interventions to improve patient outcomes in blood pressure control. Prev Med 1985; 14: 783–800

    Article  Google Scholar 

  53. McNeil BJ, Varady PD, Burrows BA, et al. Cost—effectiveness calculations in the diagnosis and treatment of hypertensive renovascular disease. N Engl J Med 1975; 293: 216–21

    Article  PubMed  CAS  Google Scholar 

  54. England WL, Grim CE, Weinberger MH, et al. Cost effectiveness in the detection of renal artery stenosis. J Gen Intern Med 1988; 3: 344–50

    Article  PubMed  CAS  Google Scholar 

  55. Nissinen A, Tuomilehto J, Kottke TE, et al. Cost—effectiveness of the North Karelia hypertension program. Med Care 1986; 24: 767–80

    Article  PubMed  CAS  Google Scholar 

  56. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation 1992; 85: 1960–8

    Article  PubMed  CAS  Google Scholar 

  57. Hamilton VH, Racicot F-E, Zowall H, et al. The cost—effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. JAMA 1995; 273: 1032–6

    Article  PubMed  CAS  Google Scholar 

  58. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med 1996; 124: 518–31

    PubMed  CAS  Google Scholar 

  59. Pharoah PD, Sanderson SP. Health promotion in primary care: modelling the impact of intervention on coronary heart disease and stroke. J Public Health Med 1995; 17: 150–6

    PubMed  CAS  Google Scholar 

  60. Goldman L, Weinstein MC, Goldman PA, et al. Cost—effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145–51

    Article  PubMed  CAS  Google Scholar 

  61. Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7

    Article  Google Scholar 

  62. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995; 91: 2274–82

    Article  PubMed  CAS  Google Scholar 

  63. Garber AM, Littenberg B, Sox HC, et al. Costs and health consequences of cholesterol screening for asymptomatic older Americans. Arch Intern Med 1991; 151: 1089–95

    Article  PubMed  CAS  Google Scholar 

  64. Benfante R, Reed D. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA 1990; 263: 393–6

    Article  PubMed  CAS  Google Scholar 

  65. Oster G, Epstein AM. Cost—effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease. JAMA 1987; 258: 2381–7

    Article  PubMed  CAS  Google Scholar 

  66. Avins AL, Browner WS. Lowering risk without lowering cholesterol: implications for national cholesterol policy. Ann Intern Med 1996; 125: 502–6

    PubMed  CAS  Google Scholar 

  67. Kinosian BP, Eisenberg JM. Cutting into cholesterol: cost—effective alternatives for treating hypercholesterolemia. JAMA 1988; 259: 2249–54

    Article  PubMed  CAS  Google Scholar 

  68. Martens LL, Rutten FFH, Erkelens DW, et al. Clinical benefits and cost—effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in the Netherlands. Am J Cardiol 1990; 65: 27F–32F

    Article  PubMed  CAS  Google Scholar 

  69. Tosteson ANA, Weinstein MC, Hunink MGM, et al. Cost—effectiveness of populationwide educational approaches to reduce serum cholesterol levels. Circulation 1997; 95: 24–30

    Article  PubMed  CAS  Google Scholar 

  70. Berwick DM, Cretin S, Keeler E. Cholesterol, children, and heart disease: an analysis of alternatives. Pediatrics 1981; 68: 721–30

    PubMed  CAS  Google Scholar 

  71. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: cost—effectiveness of pharmacologic management. JAMA 1990; 264: 3025–33

    Article  PubMed  CAS  Google Scholar 

  72. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patient with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443–50

    Article  PubMed  CAS  Google Scholar 

  73. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 25–8

    Article  Google Scholar 

  74. Pilote L, Granger C, Armstrong PW, et al. Differences in the treatment of myocardial infarction between the United States and Canada: a survey of physicians in the GUSTO trial. Med Care 1995; 33: 598–610

    Article  PubMed  CAS  Google Scholar 

  75. Darling GM, Johns JA, McCloud PI, et al. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337: 595–601

    Article  PubMed  CAS  Google Scholar 

  76. Boushey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocystene as a risk factor for vascular disease: probable benefits of increasing folic acid. JAMA 1995; 274: 1049–57

    Article  PubMed  CAS  Google Scholar 

  77. Gustaffson C, Asplund K, Britton M, et al. Cost—effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspectives. BMJ 1992; 305: 1457–60

    Article  Google Scholar 

  78. Meade TW, Miller GJ. Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk. Am J Cardiol 1995; 75: 23B–6B

    Article  PubMed  CAS  Google Scholar 

  79. Aspirin to prevent heart attack or stroke. Drug Ther Bull 1994; 32: 1–3

  80. Sox HC Jr, Littenberg B, Garber AM. The role of exercise testing in screening for coronary artery disease. Ann Intern Med 1989; 1110: 456–69

    Google Scholar 

  81. Weinstein MC. Economic assessment of medical practices and technologies. Med Decis Making 1981; 1: 309–30

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Public Health and Primary Care, University of Oxford, Oxford, England

    Adalsteinn D. Brown

  2. Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada

    Adalsteinn D. Brown

  3. Stamos Associates Inc., San Francisco, California, USA

    Adalsteinn D. Brown

  4. Veterans Affairs Palo Alto Health Care System and Department of Medicine, Stanford University, Stanford, California, USA

    Alan M. Garber

Authors
  1. Adalsteinn D. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan M. Garber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan M. Garber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, A.D., Garber, A.M. Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults. Pharmacoeconomics 14, 27–48 (1998). https://doi.org/10.2165/00019053-199814010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199814010-00004

Keywords

Search

Navigation